Compare ARDX & PBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARDX | PBI |
|---|---|---|
| Founded | 2007 | 1920 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Office Equipment/Supplies/Services |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2014 | N/A |
| Metric | ARDX | PBI |
|---|---|---|
| Price | $5.98 | $9.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 2 |
| Target Price | $10.65 | ★ $12.00 |
| AVG Volume (30 Days) | 2.7M | ★ 2.9M |
| Earning Date | 10-30-2025 | 10-29-2025 |
| Dividend Yield | N/A | ★ 3.28% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.45 |
| Revenue | $398,234,000.00 | ★ $1,931,125,000.00 |
| Revenue This Year | $22.71 | N/A |
| Revenue Next Year | $27.81 | N/A |
| P/E Ratio | ★ N/A | $23.13 |
| Revenue Growth | ★ 58.12 | N/A |
| 52 Week Low | $3.21 | $6.88 |
| 52 Week High | $6.78 | $13.11 |
| Indicator | ARDX | PBI |
|---|---|---|
| Relative Strength Index (RSI) | 57.69 | 46.90 |
| Support Level | $5.49 | $9.45 |
| Resistance Level | $6.02 | $10.08 |
| Average True Range (ATR) | 0.28 | 0.26 |
| MACD | 0.01 | 0.10 |
| Stochastic Oscillator | 75.00 | 72.12 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Pitney Bowes Inc is a technology-driven company that provides SaaS shipping solutions, mailing innovation, and financial services to clients around the globe. The company's reportable segments are SendTech Solutions and Presort Services. SendTech Solutions includes the revenue and related expenses from physical and digital mailing and shipping technology solutions, financing, services, supplies and other applications to help simplify and save on the sending, tracking and receiving of letters, parcels and flats. Presort Services includes the revenue and related expenses from sortation services to qualify large volumes of First Class Mail, Marketing Mail and Marketing Mail Flats/Bound Printed Matter for postal worksharing discounts. It derives maximum revenue from SendTech Solutions.